WallStreetZenWallStreetZen

NASDAQ: XERS
Xeris Biopharma Holdings Inc Stock

$2.57+0.09 (+3.63%)
Updated Jul 16, 2024
XERS Price
$2.57
Fair Value Price
N/A
Market Cap
$381.02M
52 Week Low
$1.46
52 Week High
$3.26
P/E
-5.59x
P/B
-41.51x
P/S
1.81x
PEG
N/A
Dividend Yield
N/A
Revenue
$171.36M
Earnings
-$64.40M
Gross Margin
82.9%
Operating Margin
-22.13%
Profit Margin
-37.6%
Debt to Equity
-37.68
Operating Cash Flow
-$41M
Beta
1.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

XERS Overview

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XERS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

XERS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XERS is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
XERS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more XERS due diligence checks available for Premium users.

Be the first to know about important XERS news, forecast changes, insider trades & much more!

XERS News

Valuation

XERS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-5.59x
Industry
-18x
Market
31.71x

XERS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-41.51x
Industry
6.51x

XERS's financial health

Profit margin

Revenue
$40.6M
Net Income
-$19.0M
Profit Margin
-46.7%
XERS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
XERS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$336.6M
Liabilities
$345.8M
Debt to equity
-37.68
XERS's short-term assets ($173.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XERS's long-term liabilities ($272.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XERS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XERS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$20.3M
Investing
-$19.7M
Financing
$35.2M
XERS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

XERS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
XERS$381.02M+3.63%-5.59x-41.51x
CABA$379.45M+0.64%-4.57x1.71x
ACIU$384.89M+5.15%-5.79x2.42x
VRCA$373.72M+5.26%-5.01x247.83x
AGEN$371.69M+13.46%-1.40x-1.85x

Xeris Biopharma Holdings Stock FAQ

What is Xeris Biopharma Holdings's quote symbol?

(NASDAQ: XERS) Xeris Biopharma Holdings trades on the NASDAQ under the ticker symbol XERS. Xeris Biopharma Holdings stock quotes can also be displayed as NASDAQ: XERS.

If you're new to stock investing, here's how to buy Xeris Biopharma Holdings stock.

What is the 52 week high and low for Xeris Biopharma Holdings (NASDAQ: XERS)?

(NASDAQ: XERS) Xeris Biopharma Holdings's 52-week high was $3.26, and its 52-week low was $1.46. It is currently -21.17% from its 52-week high and 76.03% from its 52-week low.

How much is Xeris Biopharma Holdings stock worth today?

(NASDAQ: XERS) Xeris Biopharma Holdings currently has 148,255,663 outstanding shares. With Xeris Biopharma Holdings stock trading at $2.57 per share, the total value of Xeris Biopharma Holdings stock (market capitalization) is $381.02M.

Xeris Biopharma Holdings stock was originally listed at a price of $20.22 in Jun 21, 2018. If you had invested in Xeris Biopharma Holdings stock at $20.22, your return over the last 6 years would have been -87.29%, for an annualized return of -29.09% (not including any dividends or dividend reinvestments).

How much is Xeris Biopharma Holdings's stock price per share?

(NASDAQ: XERS) Xeris Biopharma Holdings stock price per share is $2.57 today (as of Jul 16, 2024).

What is Xeris Biopharma Holdings's Market Cap?

(NASDAQ: XERS) Xeris Biopharma Holdings's market cap is $381.02M, as of Jul 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Xeris Biopharma Holdings's market cap is calculated by multiplying XERS's current stock price of $2.57 by XERS's total outstanding shares of 148,255,663.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.